Market Place
Sourcing Support
All News #Library
Biotech
Recode Therapeutics Starts Enrollment of Phase 2 Trial Of RCT2100
17 Nov 2025 //
BUSINESSWIRE
Recode Therapeutics Secures $29m For Genetic Medicines Pipeline
29 Sep 2025 //
BUSINESSWIRE
ReCode Receives Funding from CF Foundation for Gene Therapies
18 Nov 2024 //
BUSINESSWIRE
ReCode Doses First Patient In CF Clinical Study
26 Sep 2024 //
BUSINESSWIRE
ReCode Therapeutics to Participate in Upcoming Investor Conferences
25 Sep 2024 //
BUSINESSWIRE
ReCode Announces First Participants Dosed in a Phase 1 Study of RCT2100
21 Feb 2024 //
BUSINESSWIRE
ReCode Doses First Patient in Phase 1 Clinical Study of Novel mRNA-based Therapy
03 Jan 2024 //
BUSINESSWIRE
ReCode Appoints Erica Jefferson as Senior Vice President of Corporate Affairs
10 Jul 2023 //
BUSINESSWIRE
ReCode Therapeutics to Present at Jefferies Healthcare Conference
02 Jun 2023 //
BUSINESSWIRE
ReCode Announces First Participants Dosed in a Phase 1 Trial of RCT1100
15 Mar 2023 //
BUSINESSWIRE
ReCode Announces Strategic Investment from the Cystic Fibrosis Foundation
10 Jan 2023 //
BUSINESSWIRE
AskBio to Collaborate with ReCode for Single Vector Gene Editing Platform
09 Jan 2023 //
PR NEWSWIRE
ReCode Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
03 Jan 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.